Fatal bilateral intracerebral hemorrhage following treatment with alemtuzumab for multiple sclerosis

Background Alemtuzumab is approved for treating multiple sclerosis. It can, however, cause intracerebral hemorrhage (ICH) mediated by an immune thrombocytopenia. So far, only one fatal case of ICH following alemtuzumab treatment in a patient with a normal platelet count has been reported. A connection to alemtuzumab could, however, not be verified because no autopsy was performed on the deceased.